MET and non-small cell lung carcinoma: Encouraging results were obtained in clinical studies for non-small cell lung cancer (NSCLC) with MEK inhibitors including trametinib; however, in CRC, it was observed that a MEK inhibitor, AZD6244, caused the upregulation of c-MET/JAK/STAT signaling as an adaptive resistance mechanism.